ClinicalTrials.gg
CompletedNCT05743608RESPONSEUpdated Sep 9, 2025

NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients

An observational study in COPD, sponsored by Chiesi Hungary Ltd.. Completed at 39 sites in Hungary. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Chiesi Hungary Ltd. (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,336
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Chiesi Farmaceutici S.p.A..

Started
2023
with 2 others
Observational
9 of 68
5 open now
Registered
60th of 68
by date

Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is one of 3 that started in 2023, is one of 9 observational ones, and was the 60th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

5 of the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The goal of this observational study is to measure improvement in health related quality of life in moderate to severe COPD patients treated with Trimbow inhalation powder. The main question[s] it aims to answer are:

  • Treatment's effect on quality of life
  • Treatment's effect on lung function Participants will be assessed according to routine clinica practice, without any additional intervention.
Read the detailed description

COPD is a severe and very common disease affecting a large proportion of smokers (and even non-smokers) all around the world. With the large prevalence and wide spectrum of disease presentation (from limited obstruction to life threatening conditions) there is a need for differentiated, targeted approach to therapy. For this purpose, plenty of inhaler devices had been developed. Chiesi is the only company which provides fix triple combinations in both DPI and pMDI formulations. While there is ample data from multiple studies on the real-world effectiveness of the pMDI, there is a relevant gap in our knowledge on the RWE effectiveness of the DPI device Trimbow dry powder inhaler is a novel extrafine, single inhaler triple therapy, in a state of the art dry powder inhaler, which is easy to use and may provide additional benefit to a large proportion of COPD patients. However, there are only a limited number of studies assessing its effectiveness, especially in patients with moderate airflow obstruction. Providing more real-world evidence that Trimbow® dry powder inhaler is an effective and preferred treatment option in reducing symptoms and improving lung function in all COPD patients, would help pulmonologists choose the most suitable treatment option for a very wide array of patients.

03

Conditions studied

  • COPD

Keywords

  • COPD
  • CAT
  • Fixed-dose triple inhaled therapy
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Moderate to severe COPD patients who are uncontrolled on either LABA/LAMA or ICS/LABA fixed dose dual combination therapy, and had been switched to Trimbow dry powder inhaler prior to study inclusion

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient had been diagnosed with for over a year by a pulmonologists specialist
  • Patients ≥ 35 years of age
  • outpatient
  • Having had a spirometry test performed maximum 1 month prior to inclusion OR on the day of study inclusion
  • Eligibility to Trimbow 88/5/9 µg inhalation powder treatment according to SmPC:

    • having a moderate or severe obstruction (30%≤\<80%)
    • uncontrolled despite fixed dual combination treatment (LABA/LAMA or ICS/LABA):

      • at least 1 severe or 2 moderate exacerbations (requiring hospital admission) in the past 12 months
      • symptomatic patient (CAT≥10 and/or mMRC ≥2)
  • Therapy was changed to Trimbow® 88/5/9 µg inhalation powder maximum 1 week prior to or on the day of study inclusion and irrespective of study entry (escalation of symptomatic patient to fixed triple combination as per treatment protocol)
  • Patient provided to study participation and related data collected
  • Patient with no functional disability

Exclusion criteria

Exclusion criteria:

  • Participation in any clinical trial, 30 days prior to inclusion
  • Ongoing severe exacerbation (requiring hospitalisation) or severe exacerbation within the last 4 weeks
  • Diagnosis of asthma (asthma/ co-occurrence - ACO not allowed!)
  • Continuous use of oral or oxygen therapy
  • Patients with other important diseases of the respiratory system or other organ systems that may significantly contribute to COPD symptoms (such as untreated heart failure, symptomatic anaemia, etc.)
  • Any additional listed in the SmPC for Trimbow® 88/5/9 µg inhalation powder and any other provision in the SmPC that would prevent the patient from receiving fixed triple combination therapy
  • The patient is unable to complete the part of the questionnaire(s) relevant to him/her
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,336 participants (actual)
Patient registry
No

Groups and cohorts

  • Moderate to severe COPD patients receiving Trimbow dry powder inhaler

    Patients above the age of 35 years, who had been diagnosed with COPD for over a year by a pulmonologists specialist. Having a moderate or severe obstruction (30%≤FEV1\<80%) and are uncontrolled despite fixed dual combination treatment (LABA/LAMA or ICS/LABA). Therapy was changed to Trimbow® 88/5/9 µg inhalation powder maximum 1 week prior to or on the day of study inclusion and irrespective of study entry (escalation of symptomatic patient to fixed triple combination as per treatment protocol)

06

What researchers measure

Primary outcomes

  1. COPD Assessment Test (CAT)

    Change in symptom scores (COPD Assessment Test - CAT) after six months of treatment. On a scale of 0-40

    Time frame: 6 months

Secondary outcomes

  1. Lung function - Forces Expiratory flow in 1 second (FEV1)

    Change in FEV1 values after inhalation during 6 months of treatment compared to baseline.

    Time frame: 6 months

  2. Lung function Forced Vital Capacity (FVC)

    Change in FVC values after inhalation during 6 months of treatment compared to baseline.

    Time frame: 6 months

  3. Responders

    Percentage of patients with a change from baseline 2\< in CAT after 6 months of treatment compared to baseline (assessment of response to therapy).

    Time frame: 6 months

  4. Health Related Quality of Life (HRQoL) - questions

    To assess changes in quality of life in EQ-5D-3L domains after 6 months of treatment compared to baseline. Scale on a level of three

    Time frame: 6 months

  5. HRQoL - VAS

    To assess changes in quality of life in EQ-5D visual analogue scale (VAS) after 6 months of treatment compared to baseline. Scale from 0-100

    Time frame: 6 months

  6. Symptoms

    To assess changes in frequency of cough and sputum production after 6 months of treatment compared to baseline.

    Time frame: 6 months

  7. Saturation

    To assess changes in arterial oxygenation compared to baseline oxigen saturation (SpO2) after 6 months of treatment.

    Time frame: 6 months

  8. Adherence

    To assess changes in adherence to inhaler treatment according to the TAI (Test of adherence to inhalers) questionnaire after 6 months of treatment compared to baseline. Scale is from 12-54

    Time frame: 6 months

  9. Night-time symptoms

    To assess changes in the frequency of night-time symptoms after 6 months of treatment compared to baseline.

    Time frame: 6 months

  10. mMRC

    To assess changes in dyspnoea severity using the mMRC (modified Medical Research Council) questionnaire after 6 months of treatment compared to baseline. Scale from 1-4

    Time frame: 6 months

07

Study locations

39 sites
  • Albert Schweitzer Kórház és Rendelőintézet Tüdőbeteggondozó
    Aszód, Hungary
  • Bajai Szent Rókus Kórház, Tüdőbeteggondozó Intézet
    Baja, Hungary
  • National Korányi Institute of Pulmonology
    Budapest, 1122, Hungary
  • Bajcsy -Zsilinszky Kórház és Rendelőintézet
    Budapest, Hungary
  • Józsefvárosi Szent Kozma Egészségügyi Központ Tüdőgyógyászat és Gondozó
    Budapest, Hungary
  • Kispesti Egészségügyi Intézet Tüdőgondozó, Ernyőképszűrő állomás
    Budapest, Hungary
  • Szent Kristóf Szakrendelő Tüdőgondozó
    Budapest, Hungary
  • Toldy Ferenc Kórház és Rendelőintézet I. Tüdőgondozó
    Cegléd, Hungary
  • Csornai Margit Kórház Tüdőbeteggondozó Intézet
    Csorna, Hungary
  • Debreceni Egyetem Klinikai Központ, Kenézy Gyula Campus Pulmonológiai részleg
    Debrecen, Hungary
  • Dombóvári Szent Lukács Kórház, Tüdőbeteggondozó, Dombóvár I.
    Dombóvár, Hungary
  • Dorogi Szent Borbála Szakkórház és Szakorvosi Rendelő
    Dorog, Hungary
  • Szent Pantaleon Kórház Rendelőintézet Dunaújváros
    Dunaújváros, Hungary
  • Vaszary Kolos Kórház Tüdőgondozó Esztergom
    Esztergom, Hungary
  • Bugát Pál Kórház Tüdőbeteg Gondozó Intézet
    Gyöngyös, Hungary
  • Békés Megyei Központi Kórház 1. Tüdőgyógyászat Szakrendelés
    Gyula, Hungary
  • Jászberényi Szent Erzsébet Kórház Tüdőgyógyászat Járóbeteg ellátás
    Jászberény, Hungary
  • Lumniczer Sándor Kórház-Rendelőintézet Tüdőgondozó
    Kapuvár, Hungary
  • Kátai Gábor Kórház Tüdőgyógyászati Szakrendelés
    Karcag, Hungary
  • Bács-Kiskun Megyei Kórház Tüdőgondozó Szakrendelés
    Kecskemét, Hungary
  • Keszthelyi Kórház Tüdőgondozó
    Keszthely, Hungary
  • Szent Damján Görögkatolikus Kórház Tüdőgyógyászati gondozó 1.
    Kisvárda, Hungary
  • Selye János Kórház Tüdőgyógyászati Szakellátás
    Komárom, Hungary
  • Kunszentmárton Városi Egészségügyi Központ Tüdőgyógyászat
    Kunszentmárton, Hungary
  • Szaplonczay Manó Marcali Kórház, Tüdőgyógyászati Szakrendelés
    Marcali, Hungary
  • Mohácsi Kórház, Tüdőbeteggondozó
    Mohács, Hungary
  • Karolina Kórház-Rendelőintézet Mosonmagyaróvár
    Mosonmagyaróvár, Hungary
  • Nagyatádi Kórház Tüdőgondozó
    Nagyatád, Hungary
  • FM Magánklinika Eü. Szolg. Kft.
    Nyíregyháza, Hungary
  • Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház
    Nyíregyháza, Hungary
  • Orosházi Kórház Tüdőgondozó
    Orosháza, Hungary
  • Oroszlányi Szakorvosi és Ápolási Intézet Tüdőgyógyászat
    Oroszlány, Hungary
  • Egyesített Egészségügyi Intézmények, Tüdőgondozó
    Pécs, Hungary
  • Szent Lázár Megyei Kórház, Tüdőbeteggondozó Szakrendelő
    Salgótarján, Hungary
  • Sarkadi Kistérségi Egészségügyi Fejlesztő Nonprofit Kft.
    Sarkad, Hungary
  • Békés Megyei Képviselő-testület Pándy Kálmán Kórháza Tüdőgondozó
    Szeghalom, Hungary
  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőintézet Tüdőgyógyászati Szakrendelés
    Szolnok, Hungary
  • Markusovszky Egyetemi Oktatókorház
    Szombathely, Hungary
  • Zala Megyei Szent Rafael Kórház Pulmonológia, Allergológiai és Asztma Szakrendelés
    Zalaegerszeg, Hungary
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Oct 2024, 19 months.

Of 120 industry-sponsored observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 19 months is close to that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Feb 24, 2023
StartActual
Mar 29, 2023
Primary completionActual
Oct 31, 2024
CompletionActual
May 5, 2025
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05743608
Collaborators
Chiesi Slovenija, d.o.o., Chiesi Bulgaria, CHIESI CZ s.r.o.
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Mar 29, 2023
Primary completion
Oct 31, 2024
Completion
May 5, 2025
Last update
Sep 9, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion